Hot News

搶完疫苗搶藥丸 香港擬采購默克新冠口服錠 1療程700元 @ 2021-10-04T12: Back Hot News
Keyword:新冠口服藥 默克 默沙東 死亡 藥廠
Concept:默沙東藥廠新冠口服藥
美國默克藥廠(MERCK,又稱默沙東、MSD)宣布臨床實驗證實,其研發的口服新藥「MOLNUPIRAVIR」能夠大幅降低新冠患者的重症住院或死亡風險。
除了新冠疫苗的研發之外,新冠藥物是影響疫情走向的下個決戰點,美國藥廠默沙東(MERCK)研發新冠口服藥 MOLNUPIRAVIR ,如今公布臨床研究報告,發現有效降低 50 %死亡或重症住院機率,尤其台灣這次其實也有參與在臨床實驗,未來采購可能還更具有談判優勢,對此中央流行指揮中心指揮官陳時中昨(3)日記者會表示:「程序都在進行中。」
美國默克藥廠(默沙東,MERCK)1日公布的臨床試驗期中結果顯示,實驗性的新冠口服藥物莫奈拉韋(暫譯MOLNUPIRAVIR),可降低50%的死亡或重症住院機率,也正積極尋求美國的緊急授權(EUA)。指揮中心指揮官陳時中也說正籌備口服藥物,但不代表可完全取代疫苗,而是部署三道防線抵擋疫情。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.